Israel-based OptoLight Vision Technology received a European CE mark of compliance with health and safety legislation for its Lipshitz Macular Implant and will begin global marketing. A statement from the company said that the device was created for patients with age-related macular degeneration and other degenerative retinal diseases. It integrates miniature mirrors to form a mirror telescope inside the eye and is the only implantable telescope that can magnify the central image without diminishing peripheral vision.

"We are very pleased that a significant number of macular degeneration patients that until now had no medical treatment at all will be able to improve their vision by using our LMI technology," said Dr. Isaac Lipshitz, inventor and chief executive officer of OptoLight. "The mirror telescope is a technological platform that will also enable us to help patients with other retinal disorders that have no effective medical treatment."